Discover this podcast and so much more

Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

Risk-taking and Dealmaking with Global MedTech Leader, Kevin Lobo

Risk-taking and Dealmaking with Global MedTech Leader, Kevin Lobo

FromRedefiners


Risk-taking and Dealmaking with Global MedTech Leader, Kevin Lobo

FromRedefiners

ratings:
Length:
30 minutes
Released:
Jul 13, 2022
Format:
Podcast episode

Description

Take risks, keep learning, and stay calm. It’s how our guest, Stryker Chair and CEO Kevin Lobo, became arguably one of the most successful CEOs ever. We’ll talk with the Indian-born, Canadian-raised, internationally acclaimed businessperson about how he became known as the “Godfather of MedTech” and as an acquisitions deal maker. We’ll hear how Kevin’s high threshold for risk helped Stryker drastically outpace the competition and how he built his Board’s trust to make more than 55 acquisitions. Kevin also shares his insights on timely topics leaders in all industries are talking about: technology, crisis management, company culture, and how to keep employees happy, purpose-driven, and loyal.   
If you liked this episode, check out these other Redefiner episodes:·  Trust Your Gut: AXA’s Thomas Buberl Talks Transformation and Reinvention·  How to Lead Like a Legend with Samuel Tsien·  Confessions of a Serial Entrepreneur with Mario Schlosser BIO: Kevin A. Lobo, Chair and CEO, StrykerKevin A. Lobo has been CEO of Stryker since October 1, 2012, and also assumed the role of Chair of the Board on July 22, 2014. He joined Stryker in 2011 and had previously been Group President of Orthopaedics. Mr. Lobo serves on the board of directors for Parker Hannifin Corporation (NYSE:PH), the Advanced Medical Technology Association (AdvaMed) and the U.S.-India Business Council. He is also a member of the Business Roundtable and Business Council.
Mr. Lobo has a broad business career across multiple industries. After holding finance positions with KPMG, Unilever and Kraft Canada, he spent eight years with Rhone-Poulenc, including roles based in Europe as Corporate Controller of a chemical spin-out and General Manager of Specialty Phosphates EMEA. He then spent eight years at Johnson & Johnson, including President of Ethicon Endo Surgery.
Released:
Jul 13, 2022
Format:
Podcast episode

Titles in the series (69)

Call them changemakers. Call them rule breakers. We call them Redefiners. And in this provocative podcast, we explore how daring leaders from across industries and around the globe are redefining their organizations—and themselves—to create extraordinary impact in today’s rapidly changing world. In each episode, Russell Reynolds Associates consultant Nanaz Mohtashami and CEO Clarke Murphy host engaging, purposeful conversations with leaders in and out of the business world who share their insights and perspectives on how they lead, boldly. You’ll come away with fresh ideas and tangible takeaways on how you can redefine your own leadership trajectory – no matter where you are on your journey.    Our Hosts: Clarke Murphy  Clarke Murphy is the Chief Executive Officer of Russell Reynolds Associates and serves on the Board of Directors. Prior to his appointment as CEO, he was the Global Leader of the firm's CEO/Board Services Practice.​  While at Russell Reynolds Associate​s, Clarke has conducted a number of significant projects in the industry, including Fortune 100 board searches and CEO successions. In addition, he has led notable searches in​​ the private equity industry including searches ​for the Carlyle Group and Warburg Pincus. Nanaz Mohtashami Nanaz Mohtashami is Managing Director at Russell Reynolds Associates, a core member of the firm’s Healthcare Sector, and leads the Medtech Practice in Europe. She devises global strategies for healthcare clients across devices, diagnostics, and pharma, as well as for private equity clients around the world. Nanaz focuses on leadership assignments at the executive and non-executive levels, tackling a wide array of senior talent issues such as succession, development, team effectiveness, and more. She is based in London but spends a significant amount of her time across Europe and the United States.